高肿瘤突变负荷的ALK阳性肺癌快速获得阿来替尼耐药
该研究通过一例51岁男性ALK阳性晚期肺癌患者快速(3个月)出现阿来替尼耐药的尸检样本,建立耐药细胞系和PDX模型,发现高肿瘤突变负荷和异质性肿瘤演化可能介导快速耐药,及时使用劳拉替尼或联合其他受体酪氨酸激酶抑制剂可能有效。
要点
- 高肿瘤突变负荷和异质性演化与阿来替尼快速耐药相关
- 不同转移灶可检出不同ALK G1202R核苷酸改变
- 劳拉替尼或ALK抑制剂联合其他RTK抑制剂可能克服耐药
核心结论
- 高肿瘤突变负荷和异质性肿瘤演化可能是快速获得阿来替尼耐药的原因。
- 及时使用劳拉替尼或ALK抑制剂联合其他受体酪氨酸激酶抑制剂可能是有效策略。
研究设计与样本
- 病例来源为1例51岁男性ALK阳性晚期肺癌患者,经阿来替尼治疗3个月后出现耐药。
- 获取肺、肝、肾肿瘤尸检样本,从胸腔积液建立阿来替尼耐药细胞系ABC-14,从肝肿瘤建立阿来替尼/克唑替尼耐药细胞系ABC-17及PDX模型。
- 采用下一代测序、直接DNA测序和定量实时逆转录聚合酶链反应进行检测。
主要发现
- ABC-14细胞无ALK突变,对克唑替尼敏感,同时呈现MET基因扩增和双调蛋白过表达,克唑替尼联合厄洛替尼抑制细胞生长。
- ABC-17和PDX肿瘤携带ALK G1202R,PDX肿瘤在体内转移至多器官,劳拉替尼在体外和体内均抑制肿瘤生长。
- 下一代测序提示高肿瘤突变负荷和异质性肿瘤演化。
- 尸检肺肿瘤携带ALK G1202R(c.3604 G>A),右肾转移灶携带ALK G1202R(c.3604 G>C),突变涉及不同密码子改变。
临床怎么用
- 对阿来替尼快速耐药患者,可考虑及时使用劳拉替尼。
- 可探索ALK抑制剂联合其他受体酪氨酸激酶抑制剂的联合治疗策略。
- 耐药后应关注肿瘤突变负荷和异质性演化,必要时多部位活检。
局限性
- 证据基于单例患者来源的细胞系和PDX模型,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The highly selective ALK receptor tyrosine kinase (ALK) inhibitor alectinib is standard therapy for ALK-positive lung cancers; however, some tumors quickly develop resistance. Here, we investigated the mechanism associated with rapid acquisition of resistance using clinical samples. METHODS: Autopsied samples were obtained from lung, liver, and renal tumors from a 51-year-old male patient with advanced ALK-positive lung cancer who had acquired resistance to alectinib in only 3 months. We established an alectinib-resistant cell line (ABC-14) from pleural effusion and an alectinib/crizotinib-resistant cell line (ABC-17) and patient-derived xenograft (PDX) model from liver tumors. Additionally, we performed next-generation sequencing, direct DNA sequencing, and quantitative real-time reverse transcription polymerase chain reaction. RESULTS: ABC-14 cells harbored no ALK mutations and were sensitive to crizotinib while also exhibiting MNNG HOS transforming gene (MET) gene amplification and amphiregulin overexpression. Additionally, combined treatment with crizotinib/erlotinib inhibited cell growth. ABC-17 and PDX tumors harbored ALK G1202R, and PDX tumors metastasized to multiple organs in vivo, whereas the third-generation ALK-inhibitor, lorlatinib, diminished tumor growth in vitro and in vivo. Next-generation sequencing indicated high tumor mutation burden and heterogeneous tumor evolution. The autopsied lung tumors harbored ALK G1202R (c. 3604 G>A) and the right renal metastasis harbored ALK G1202R (c. 3604 G>C); the mutation thus comprised different codon changes. CONCLUSIONS: High tumor mutation burden and heterogeneous tumor evolution might be responsible for rapid acquisition of alectinib resistance. Timely lorlatinib administration or combined therapy with an ALK inhibitor and other receptor tyrosine-kinase inhibitors might constitute a potent strategy.
引用
- Makimoto G, Ohashi K, Tomida S, et al. Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. J Thorac Oncol. 2019. PMID: 31374369. doi:10.1016/j.jtho.2019.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。